Double anti-drugs are in the air! Xencor and Atreca collaborated to develop CD3/tumor new antigen bispecific antibodies, the medical mammoth.

Nearly 100 authoritative leaders of domestic bio innovative drugs have spoken, hundreds of leading Biopharmaceutical Enterprises have paid close attention to it. More than 1000 pharmaceutical peers have signed up to participate. Dozens of innovative drug technologies have been collectively unveiled. Four hot biomedical fields, including tumor immunity, new antibodies, stem cell regenerative medicine, and gene therapy, are focused on. 2020 bpit The biopharmaceutical innovation technology conference will be held in Nanjing International Youth Cultural Center. From July 19 to 21, 2020, we will pay tribute to the next golden decade of innovative drugs and witness the new goals and new mileage of Chinese innovative drugs! This article is originally created by emameck, welcome to share, and reprinted with authorization. July 11, 2020 / emedclub news / - - recently, xencor and atreca reached an agreement to jointly discover, develop and commercialize t-cell-bound bispecific antibodies as a potential treatment for cancer.under the agreement, the two companies will conduct a three-year discovery program.atreca will provide antibodies against new tumor targets, and xencor is responsible for transforming these antibodies into xmab bispecific antibodies.at most two joint plans are selected for further development and commercialization, with 50% of the cost and profit borne by each company.Dr. Bassil dahiyat, President and CEO of xencor, said: "xencor is building a wide range of candidate drug combinations based on the xmab? Technology platform, which enables us to create new mechanisms with enhanced properties, therapeutic antibodies and other proteins.based on its unique discovery platform, atreca provides new tumor selective antibodies and targets to participate in cytotoxic T cells killing tumor cells.this collaboration provides new opportunities for xencor and atreca to develop new and first-class CD3 bispecific antibodies as potential therapies for cancer patients."CD3 targeted xmab double antibody according to the information in the press release, the main target of cooperation between the two companies is the bispecific antibody (double antibody) targeting CD3.it is well known that double antibody is composed of two different binding domains, which can bind two different antigens or two different epitopes of the same antigen.the double antibody developed by this cooperation is that one binding domain binds to CD3 on T cells, and the other binds to tumor specific antigen.through this CD3 targeted double antibody, T cells and tumor target cells can be connected to achieve better tumor killing ability of T cells.in addition, the cooperation will also make full use of xencor's xmab? Engineering platform to design and manufacture CD3 double antibody, as well as through immune repertoire capture? (IRC) ™） The technology recognizes the unique targeted antibodies produced by the human immune system during the active immune response to tumors and captures them to produce new targeted antibodies.} xmab double antibody (image source: xencor) xencor's xmab? Bispecific Fc domain technology can maintain the full-length antibody characteristics of the double antibody, and make the candidate products have long cycle half-life and stability specificity, and can be prepared and purified by standard antibody production methods.xencor's xmab? Platform candidate products have been proven to be highly effective and well tolerated against target cells in a variety of in vivo and in vitro models.atreca's patent R & D platform immune repertoire capture (IRC) ™） The technology can naturally pair the antibody light chain produced by a single effector B cell isolated from the patient's blood sample, correct bias and correct error, so that all the antibodies of the patient can be generated in the active immunity in the way of target unknowable, and select the antibody sequence for the early gene synthesis and expression.CD3: a hot target of double antibody. In fact, in the field of tumor immunotherapy, the research and development of antibody drugs has always been a hot direction.among them, due to the unique advantages of double antibody, the research and development of double antibody drugs has not fallen behind.in recent years, we can find that CD3 is a multiple target in the development of bispecific antibodies.currently, there are three bispecific antibody drugs approved for marketing in the world, and two of them target CD3.in 2009, the European Union approved the first therapeutic bispecific antibody, catumaxomab (targeting CD3 and EpCAM) of Trion pharma company. Its structure is a three functional bispecific antibody (triomab) for the treatment of malignant ascites.due to the miserable market sales situation, the official announcement was withdrawn from the market permanently in June 2017.at present, the dual antibody is preparing to be re marketed, and has obtained the clinical implied license in China, and the indication is advanced gastric cancer with peritoneal metastasis that is not suitable for systemic treatment.in 2014, FDA quickly approved blincyto (blinatumomab, targeting CD3 and CD19), a bispecific antibody drug developed by Amgen (Amgen) company based on bite technology, for the treatment of acute B-lymphoblastic leukemia. It is also the first drug approved to target CD19.in October 2019, Amgen CD3 / CD19 double antibody, blinatumomab for injection, was listed in China.in November 2017, FDA quickly approved Roche's bispecific antibodies, emicizumab (targeting coagulation factor X and factor IXa), for the treatment of hemophilia.in December 2018, it was the first bispecific antibody drug approved in China.in addition, many large companies, such as Roche, antalyl and regenerant, are laying out CD3 targeted double antibodies.focusing on four popular biomedical fields, such as tumor immunity, new antibodies, stem cell regenerative medicine and gene therapy, the 2020 bpit biopharmaceutical innovation technology conference will be held in Nanjing International Youth Culture Center, China, on July 19-21, 2020! Click the picture above to view the agenda of the conference